Navigation Links
CASI Pharmaceuticals Reports Second Quarter 2014 Financial Results
Date:8/14/2014

hepatocellular carcinoma.

About CASI Pharmaceuticals, Inc.CASI is a clinical-stage pharmaceutical company employing a drug-development strategy that leverages resources in both North America and in China to develop therapeutics for the treatment of cancer and other diseases.  Its lead compound is ENMD-2076, a selective angiogenic kinase inhibitor that has completed Phase I studies in solid tumors, multiple myeloma and leukemia.  CASI is conducting Phase II studies with ENMD-2076 in triple-negative breast cancer, advanced/metastatic soft tissue sarcoma and advanced ovarian clear cell carcinomas.  The Company is headquartered in Rockville, Maryland and has a wholly owned subsidiary and R&D Center in Beijing, China.  Additional information about CASI is available at www.casipharmaceuticals.com and in various filings with the U.S. Securities and Exchange Commission.

Forward Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals.  Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed.

Actual results could differ materially from those currently anticipated due to a number of factors, including: the risk that we may be unable to continue as a going concern as a result of our inability to raise sufficient capital for our operational needs; the possibility that we may be delisted from trading on the Nasdaq Capital Market; the volatility in the market price of our common stock; t
'/>"/>

SOURCE CASI Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Immune Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Update on Bertilimumab Commencement of Phase II Clinical Trials
2. Imprimis Pharmaceuticals Announces Second Quarter 2014 Financial Results and Provides Operational Update
3. Dipexium Pharmaceuticals Reports Second Quarter 2014 Financial and Operational Results
4. Valeant Pharmaceuticals Receives FTC Second Request Under Hart-Scott-Rodino
5. Rock Creek Pharmaceuticals Reports Second Quarter and Announces Clinical Update
6. AcelRx Pharmaceuticals Reports Second Quarter 2014 Financial Results
7. Inovio Pharmaceuticals Reports 2014 Second Quarter Financial Results
8. Absorption Pharmaceuticals CEO Jeff Abraham Discusses Promescent on KFI
9. Global Diabetic Neuropathy Market 2014-2018: Key Vendors are Eli Lilly and Co, Janssen Pharmaceuticals and Pfizer Inc.
10. Jazz Pharmaceuticals Announces Pricing of $500 Million of Exchangeable Senior Notes
11. AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Nov. 25, 2014  Medtronic,s roughly $43 ... been widely discussed in the media for its ... a stronger leading player in one of the ... The healthcare market research firm said  the two ... a diverse set of solutions spanning inpatient to ...
(Date:11/26/2014)... Nov. 25, 2014  Array BioPharma Inc. ... that its Chief Executive Officer, Ron ... upcoming conferences.  The public is welcome to ... the Array BioPharma website:  www.arraybiopharma.com .Event: Piper ... p.m.  Eastern Time Location: Palace Hotel, New ...
(Date:11/26/2014)... NEW YORK and HERZLIYA PITUACH, Israel, Nov. ... IMNP; "Immune" or "the Company"), a clinical stage ... commercialization of targeted therapeutics for the treatment of ... of its previously announced underwritten public offering of ... share of the Company,s common stock, par value ...
Breaking Medicine Technology:Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 2Medtronic - Covidien: Beyond Taxes, Deal Will Create Patient Monitoring Power, according to Kalorama Information 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... , June 4 Amgen executive Alan ... of BeneChill, a privately held medical device company launching its ... response teams in the field, later this year in ... the pharmaceutical, biotechnology, medical device and diagnostic industries, Mr. Raffensperger ...
... BURLINGTON, Vt ., June 4 Mach 7 ... solutions, has relocated its global headquarters from suburban Chicago ... as the company,s base for Americas, sales and professional service operations, ... management and strategic R&D functions. , ...
Cached Medicine Technology:Veteran International Health Care Executive Appointed CEO of BeneChill(R) 2Mach 7 Technologies Establishes New Headquarters in Burlington, VT 2
(Date:11/26/2014)... German scientists say carbon-based synthetic molecules used ... that looks and acts similar to asbestos-induced mesothelioma. Surviving ... research. Click here to read it now. ... Experimental Medicine in Hannover injected 500 lab rats with ... eventually developed mesothelioma , how quickly it developed ...
(Date:11/26/2014)... Loffler Companies has been selected as a 2014 ... information and news publication for resellers of imaging technology, ... Loffler has earned this prestigious award and the seventh ... honor the best and the brightest in the imaging ... chosen for their innovative marketing and sales programs, community ...
(Date:11/26/2014)... 2014 Senior Planning Services, providing “expert ... nonprofit organization providing the adult demographic education and ... seniors navigate the rough seas of applying for Medicaid. ... on the topic of Medicaid eligibility and proper planning, ... of applying for this coverage. , Senior Planning ...
(Date:11/26/2014)... NY (PRWEB) November 26, 2014 Call ... research requirements or email the details on sales(at)researchmoz(dot)us ... diabetes and drug discovery market 2014" with deep study ... is the result of high blood sugar. The global ... directly linked to the growing number of diabetics in ...
(Date:11/26/2014)... 26, 2014 Louisiana Back Institute, ... specialists in minimally invasive spine surgery, announces today ... the rapidly growing provider network of orthopedic spine ... coincides with the network’s continuing success providing the ... Louisiana residents who are suffering from orthopedic spine ...
Breaking Medicine News(10 mins):Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Senior Planning Services Teams Up with SeniorNet To Educate Seniors On Medicaid Planning 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 2Health News:Latest Report on Diabetes Market 2014 - Global Market Size, Share, Trends and Forecast by Researchmoz.us 3Health News:Louisiana Back Institute Welcomes Dr. K. Samer Shamieh into Medical Provider Network 2
... with endometriosis may one day lead to new ways ... research suggests. What's more, the researchers may have also ... consequence of the condition. ,Anywhere from 10 to 15 ... when the tissue //that lines the uterus, the endometrium, ...
... take the newer, lower-dose birth control pills are not increasing ... birth control pills debuted in the 1960s, doctors have worried ... studies looking at the link, however, have looked at women ... levels of estrogen compared to those in use today. Whether ...
... may have solved the mystery of why dengue fever, unlike ... Dengue is a debilitating, sometimes fatal illness endemic to much ... by high fever, bone and muscle pain and -- in ... ,Dengue is also unusual in that //symptoms are more severe ...
... aren’t beneficial in the prevention of heart disease or ... speculated antioxidant vitamins, such as beta carotene (a form ... role in helping people avoid cardiovascular disease. The vitamins ... of dangerous plaque. Several preclinical studies show supplementing //the ...
... experienced a significant reduction in blood pressure as ... according to a new study. ,To investigate the ... the rest-activity cycle, Ramon C. Hermida, Ph.D., of ... Universitario, Spain, and colleagues studied a group of ...
... high cholesterol levels are more likely to develop high ... eating habits and cholesterol levels of nearly 450 preschool ... by doctors and had their HDL, or good cholesterol, ... the study show children with the highest levels of ...
Cached Medicine News:Health News:Scientists crack dengue fever puzzle 2Health News:Night Time Aspirin Regimen Found to Reduce Blood Pressure 2
... Stylish and comfortable eye protection ... approximately 90% of scatter radiation. Our high ... protection and comfort with minimized weight. Our ... leaded) optics that meet all industry standards. ...
Uvex Patriot Frame...
... with the safety and comfort of the practitioner ... called SF-6) leaded glass, the industry standard for ... set for optical clarity, visible light transmission, power ... protecting your eyes, it also helps you look ...
... Radiation Protection Goggles ... can be used by ... mm leaded glass, 1.0 ... shields provide increased scatter ...
Medicine Products: